Abstract:Background Hepatic fibrosis is the repair reaction of excessive deposition and abnormal distribution of extracellular matrix after various liver injuries, especially chronic HBV infection, which is a key step in the development of various chronic liver diseases to cirrhosis. Recent studies have showed that microRNAs (miRNAs) can regulate a series of liver fibrosis-related gene express and play an important role in the development of liver fibrosis. But the miRNAs expression profiling and the differentially expressed miRNAs in patients with HBV-related liver fibrosis were little known. This study aims to have a record of a systemic screening for liver fibrosis-associated miRNAs in patients infected with HBV. Methods A IlluminaHiSeq sequencing of plasma miRNAs from the HBV-related liver fibrosis patients (S2/3, n = 8) based on Scheuer's staging criteria and from healthy volunteers 42 (n = 7) was performed. Cluster analysis and target gene prediction were performed for the differentially expressed miRNAs. Gene ontology (GO) analysis and KEGG pathway enrichment analysis also were performed on the differentially expressed target miRNA genes. Results Compared with the healthy control group, 77 miRNAs were screened out from the liver fibrosis group, among which 51 miRNAs were up-regulated and 26 miRNAs were down-regulated. Eventually, miR-98-5p was identified as a candidate predictor of liver fibrosis progression. miR-98-5p is reduced in activated LX2 cells, and miR-98-5p overexpression inhibited the HSCs activation. Mechanically, MiR-98-5p prevents liver fibrosis by targeting TGFbR1 and blocking TGFb1/Smad3 signaling pathway. Furthermore, serum miR-98-5p levels were measured from a total of 70 recruited patients with chronic HBV infection and 29 healthy individuals as controls. Serum miR-98-5p level was significantly lower in patients with liver fibrosis than in healthy controls and HBV carriers. Conclusions The expression of miRNAs in patients with liver fibrosis is significantly different from that of healthy volunteers. Many signal pathways of hepatic fibrosis are regulated by miRNAs. The potential value of miR-98-5p is as diagnostic biomarkers and therapeutic targets for HBV-related liver fibrosis.

Research on Promoting Liver Fibrosis Injury by the Targeted Regulation of Mir-202 for HGF to Activate HSC

Mir-301A-3p Promotes Hepatic Stellate Cells Activation and Liver Fibrogenesis Via Regulating PTEN/PDGFR-β.

MicroRNA-101 Suppresses Liver Fibrosis by Downregulating PI3K/Akt/mTOR Signaling Pathway

Upregulation of Mirna-1228-3p Alleviates TGF-β-induced Fibrosis in Renal Tubular Epithelial Cells.

Mir-345–5P Curbs Hepatic Stellate Cell Activation and Liver Fibrosis Progression by Suppressing Hypoxia-Inducible Factor-1Alpha Expression

MiRNAs in liver fibrosis: new targets and opportunities for therapy

MiR-542-3p controls hepatic stellate cell activation and fibrosis via targeting BMP-7.

MiR-22-3p and Mir-29A-3p Synergistically Inhibit Hepatic Stellate Cell Activation by Targeting AKT3

Mir-185 Inhibits Fibrogenic Activation of Hepatic Stellate Cells and Prevents Liver Fibrosis.

Downregulation of Mir-20B-5p Contributes to the Progression of Liver Fibrosis Via the STAT3 Signaling Pathway in Vivo and in Vitro

Synergistic Antifibrotic Effects Of Mir-451 With Mir-185 Partly By Co-Targeting Ephb2 On Hepatic Stellate Cells

Mir-98-5p As a Novel Biomarker Suppress Liver Fibrosis by Targeting TGFβ Receptor 1

Mir-654-5p Contributes to the Activation and Proliferation of Hepatic Stellate Cells by Targeting RXRα

MicroRNA-212 activates hepatic stellate cells and promotes liver fibrosis via targeting SMAD7.

MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway.

MicroRNAs As Critical Regulators in Liver Fibrosis

Mir-30C Inhibits Angiogenesis by Targeting Delta-Like Ligand 4 in Liver Sinusoidal Endothelial Cell to Attenuate Liver Fibrosis.

The Autoregulatory Feedback Loop of Microrna-21/Programmed Cell Death Protein 4/activation Protein-1 (Mir-21/Pdcd4/ap-1) As a Driving Force for Hepatic Fibrosis Development.

Anti-Liver Fibrosis Role of miRNA-96-5p via Targeting FN1 and Inhibiting ECM-Receptor Interaction Pathway

Inhibition of miR‐188‐5p alleviates hepatic fibrosis by significantly reducing the activation and proliferation of HSCs through PTEN/PI3K/AKT pathway

Mir-20A-5p/tgfbr2 Axis Affects Pro-inflammatory Macrophages and Aggravates Liver Fibrosis.